
Bal Pharma API (Active Pharmaceutical Ingredients) business began in 1996 with a simple objective of facilitating the manufacture of niche molecules that have been able to take the benefits of vertical integration to international and domestic markets.
Bal Pharma’s API business has the competence and knowledge to undertake more than 30 different types of complex chemical reactions. Whether these are Advance Intermediates, Fine Chemicals or Active Pharmaceuticals Ingredients, the company can seamlessly scale up from MG to MT quantities. It offers various activities like:
State-of-the-art Pilot and Commercial Scale multipurpose facilities
Pharmaceutical Manufacturing Plants conforming to GMP guidelines
R & D facilities to support early development of Generic APIs
Patent non-infringing processes
High quality documents – Drug master file
The API products are being exported to Japan, Australia, Spain, UK, Canada, Nigeria, Iceland, Slovenia, Romania, Argentina, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, Turkey, Egypt, Korea, Venezuela, Italy, Portugal, Morocco, Poland, Netherlands, Syria, Bangladesh and Indonesia etc.
The range of APIs includes Anti-Histamine, Platelet Inhibitor, Anti-Diabetic, Anti Convulsant, Urinary Incontinence, Neuropathic Pain, Anti Allergy, Anti Inflammatory, Diuretic, Acne Treatment etc.
The plant has various accreditations.
| PRODUCTS | THERAPEUTIC USAGE | CAS NO. | DMF AVAILABLE |
|---|---|---|---|
| Adapalene | Acne treatment | 106685-40-9 | CEP |
| Alfuzosin HCL | Antihypertensive | 81403-68-1 | DMF |
| Amiloride HCL | Diuretic | 17440-83-4 | CEP |
| Aripiprazole | Antipsychotic | 129722-12-9 | CEP Filed |
| Baclofen | Muscle relaxant | 1134-47-0 | CEP Filing Q4-2025 |
| Bepotastine besilate | Antihistamine | 190786-44-8 | USDMF |
| Benzydamine HCL | Antiinflammatory | 132-69-4 | CEP |
| Dabigatran Etexilate Mesylate | Antithrombotic | 872728-81-9 | CEP Filed |
| Deferasirox | Iron Chelator | 201530-41-8 | CEP Filed |
| Ebastine | Antihistamine | 90729-43-4 | CEP |
| Epinastine HCL | Antihistamine | 108929-04-0 | DMF |
| Gliclazide | Antidiabetic | 21187-98-4 | CEP |
| Levobunolol HCL | Beta-adrenergic antagonist | 27912-14-7 | TDP |
| Paliperidone | Antipsychotic | 144598-75-4 | DMF |
| Prazosin HCL | Antihypertensive | 19237-84-4 | DMF |
| Tolterodine tartrate | Urinary incontinence | 124937-52-6 | DMF |
| Topiramate | Anticonvulsant | 97240-79-4 | CEP Filing Q4-2025 |
| Vildagliptin | Antidiabetic | 274901-16-5 | TDP |
| PRODUCTS | THERAPEUTIC USAGE | CAS NO. |
|---|---|---|
| Bilastine | Antihistamine | 202189-78-4 |
| Dapagliflozin | Antidiabetic | 461432-26-8 |
| Empagliflozin | Antidiabetic | 864070-44-0 |
| Hydrochlorothiazide | Diuretic | 58-93-5 |
| Pyrimethamine | Antiparasitic | 58-14-0 |
| PRODUCTS | THERAPEUTIC USAGE | CAS NO. |
|---|---|---|
| Apixaban | Anticoagulants | 503612-47-3 |
| Canagliflozin | Antidiabetic | 842133-18-0 |
| Cinacalcet HCL | Antihyperparathyroid | 364782-34-3 |
| Desloratadine | Antihistamine | 100643-71-8 |
| Mirabegron | Overactive bladder | 223673-61-8 |
| Rivaroxaban | Anticoagulants | 366789-02-8 |
| Semaglutide | Antidiabetic | 910463-68-2 |
| Sitagliptin Phosphate | Antidiabetic | 654671-78-0 |
| Sulfadoxine | Antimalarial | 2447-57-6 |
| Dexlansoprazole | Proton pump inhibitors | 138530-94-6 |
| Atomoxetine HCL | Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) | 82248-59-7 |
| Duloxetine HCL | Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) | 136434-34-9 |
| Rosuvastatin Calcium | Lipid-lowering agents (HMG-CoA reductase inhibitors) | 147098-20-2 |
| Download API Product list | Download API Intermediate List |